New to site?


Login

Lost password? (X)

Already have an account?


Signup

(X)
Farooq

MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics

HomenewsMedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
28
Feb
MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
  • Author
    web
  • Comments
    0 Comments
  • Category

AstraZenecaAstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio. The new company will focus on developing medicines for severe autoimmune diseases by targeting the underlying causes of each disease.Original Article

Tags:

    Related Posts
    Leave A Comment

    Leave A Comment